Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

dubermatinib (TP-0903)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Sumitomo Pharma

Drug class:

AXL inhibitor

Related drugs:

FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	TP-0903 Sensitive: C2 – Inclusion Criteria TP-0903 Sensitive : C2	TP-0903 Sensitive: C2 – Inclusion Criteria TP-0903 Sensitive : C2
AXL-L	HER2 Positive Breast Cancer	AXL-L	HER2 Positive Breast Cancer	trastuzumab + TP-0903 Sensitive: C3 – Early Trials trastuzumab + TP-0903 Sensitive : C3	trastuzumab + TP-0903 Sensitive: C3 – Early Trials trastuzumab + TP-0903 Sensitive : C3
EGFR expression	Non Small Cell Lung Cancer	EGFR expression	Non Small Cell Lung Cancer	osimertinib + TP-0903 Sensitive: C3 – Early Trials osimertinib + TP-0903 Sensitive : C3	osimertinib + TP-0903 Sensitive: C3 – Early Trials osimertinib + TP-0903 Sensitive : C3
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	TP-0903 Sensitive: C3 – Early Trials TP-0903 Sensitive : C3	TP-0903 Sensitive: C3 – Early Trials TP-0903 Sensitive : C3
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	osimertinib + TP-0903 Sensitive: C4 – Case Studies osimertinib + TP-0903 Sensitive : C4	osimertinib + TP-0903 Sensitive: C4 – Case Studies osimertinib + TP-0903 Sensitive : C4
IDH2 mutation + NRAS mutation	Acute Myelogenous Leukemia	IDH2 mutation + NRAS mutation	Acute Myelogenous Leukemia	TP-0903 Sensitive: D – Preclinical TP-0903 Sensitive : D	TP-0903 Sensitive: D – Preclinical TP-0903 Sensitive : D
MLL-PTD	Acute Myelogenous Leukemia	MLL-PTD	Acute Myelogenous Leukemia	TP-0903 Resistant: D – Preclinical TP-0903 Resistant : D	TP-0903 Resistant: D – Preclinical TP-0903 Resistant : D
WT1 mutation	Acute Myelogenous Leukemia	WT1 mutation	Acute Myelogenous Leukemia	TP-0903 Resistant: D – Preclinical TP-0903 Resistant : D	TP-0903 Resistant: D – Preclinical TP-0903 Resistant : D
SRSF2 mutation	Acute Myelogenous Leukemia	SRSF2 mutation	Acute Myelogenous Leukemia	TP-0903 Resistant: D – Preclinical TP-0903 Resistant : D	TP-0903 Resistant: D – Preclinical TP-0903 Resistant : D
ASXL1 mutation	Acute Myelogenous Leukemia	ASXL1 mutation	Acute Myelogenous Leukemia	TP-0903 Resistant: D – Preclinical TP-0903 Resistant : D	TP-0903 Resistant: D – Preclinical TP-0903 Resistant : D
FLT3 F691L	Acute Myelogenous Leukemia	FLT3 F691L	Acute Myelogenous Leukemia	TP-0903 Resistant: D – Preclinical TP-0903 Resistant : D	TP-0903 Resistant: D – Preclinical TP-0903 Resistant : D
FGFR2-AFF4 fusion	Cholangiocarcinoma	FGFR2-AFF4 fusion	Cholangiocarcinoma	pemigatinib + TP-0903 Sensitive: D – Preclinical pemigatinib + TP-0903 Sensitive : D	pemigatinib + TP-0903 Sensitive: D – Preclinical pemigatinib + TP-0903 Sensitive : D
FGFR2-AFF4 fusion	Cholangiocarcinoma	FGFR2-AFF4 fusion	Cholangiocarcinoma	TP-0903 Sensitive: D – Preclinical TP-0903 Sensitive : D	TP-0903 Sensitive: D – Preclinical TP-0903 Sensitive : D